Patients enrollment successfully completed

The enrollment phase of the clinical trial INDYGO is successfully completed, after only one year. During this study sponsored by the University Hospital of Lille (France) and with  Pr. N. Reyns as the Principal Investigator, 10 patients included from may 2017 to June 2018 have been treated with the Hemerion’s technology.

European Neurosurgery Congress

The Hemerion drug-device combination product is presented during the plenary session of annual congress of the European Association of the Neurosurgery Societies in Brussels (Be). First usability endpoints successfully collected during the Phase I INDYGO are reported to the European’s neurosurgeons community.

Awarded by world’s largest medical laser society

M. Vermandel becomes the first ever non-US resident of being the recipient of the ASLMS research grant (American Society of Lasers in Surgery and Medicine) for his work on drugs and laser technologies combination. ASLMS was founded in 1980 and is the world’s largest professional organization dedicated to the field of medical laser.


Kick-off of phase I clinical trial: INDYGO

For the first time, our technology combining a photosensitizing drug and an innovative photonic device is delivered upfront, during the surgery of patients newly diagnosed with glioblastoma.  Indygo is a Phase I study sponsored by the University Hospital of Lille.

Proof of concept

A first preclinical study proves the effectiveness of Hemerion therapeutics approach on glioblastoma (GBM) human cell lines. The experiments associated a photoactivatable drug and an innovative photonic system.

Introduction of the Hemerion technology in the USA

The Hemerion technology is demonstrated by Pr. N. Reyns at an international neurosurgery meeting in Cambridge – Boston (MA, USA) and in New-York (NY, USA) during Fluorescence-Guided Surgery Brain Tumor Symposiums hosted at The Icahn School of Medicine at Mount Sinai by Pr. C. G. Hadjipanayis.


Establishment of Hemerion Therapeutics

Hemerion Therapeutics is founded by the scientists and inventors of the technology, among them M. Vermandel, C. Dupont, N. Reyns, S. Mordon and M. Andraud gather deep scientific how-know and entrepreneurship skills to lead the company. In the mean time, Hemerion is awarded the French Tech Label that recognizes high potential start-up companies.